These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 35614465

  • 1. Down-regulation of Risa improves podocyte injury by enhancing autophagy in diabetic nephropathy.
    Su PP, Liu DW, Zhou SJ, Chen H, Wu XM, Liu ZS.
    Mil Med Res; 2022 May 26; 9(1):23. PubMed ID: 35614465
    [Abstract] [Full Text] [Related]

  • 2. LncRNA Hoxb3os protects podocytes from high glucose-induced cell injury through autophagy dependent on the Akt-mTOR signaling pathway.
    Jin J, Gong J, Zhao L, Li Y, He Q.
    Acta Biochim Pol; 2021 Oct 14; 68(4):619-625. PubMed ID: 34648253
    [Abstract] [Full Text] [Related]

  • 3. Celastrol attenuates diabetic nephropathy by upregulating SIRT1-mediated inhibition of EZH2related wnt/β-catenin signaling.
    Tang Y, Wan F, Tang X, Lin Y, Zhang H, Cao J, Yang R.
    Int Immunopharmacol; 2023 Sep 14; 122():110584. PubMed ID: 37454630
    [Abstract] [Full Text] [Related]

  • 4. Insulin-like growth factor 1 knockdown attenuates high glucose-induced podocyte injury by promoting the JAK2/STAT signalling-mediated autophagy.
    Zhang Y, Liu M, Wu Y, Xu Y, Hong Y, Xiang H.
    Nephrology (Carlton); 2024 Jul 14; 29(7):394-404. PubMed ID: 38586891
    [Abstract] [Full Text] [Related]

  • 5. LncRNA AA465934 Improves Podocyte Injury by Promoting Tristetraprolin-Mediated HMGB1 DownRegulation in Diabetic Nephropathy.
    Yang N, Zhang Y, Ren P, Zhao L, Zheng D, Fu L, Jin J.
    Mol Cell Biol; 2024 Jul 14; 44(3):87-102. PubMed ID: 38520226
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of p53/miR-34a/SIRT1 axis ameliorates podocyte injury in diabetic nephropathy.
    Liang Y, Liu H, Zhu J, Song N, Lu Z, Fang Y, Teng J, Dai Y, Ding X.
    Biochem Biophys Res Commun; 2021 Jun 25; 559():48-55. PubMed ID: 33932899
    [Abstract] [Full Text] [Related]

  • 7. Sarsasapogenin restores podocyte autophagy in diabetic nephropathy by targeting GSK3β signaling pathway.
    Li XZ, Jiang H, Xu L, Liu YQ, Tang JW, Shi JS, Yu XJ, Wang X, Du L, Lu Q, Li CL, Liu YW, Yin XX.
    Biochem Pharmacol; 2021 Oct 25; 192():114675. PubMed ID: 34252407
    [Abstract] [Full Text] [Related]

  • 8. miR-1187 induces podocyte injury and diabetic nephropathy through autophagy.
    Chen B, He Q.
    Diab Vasc Dis Res; 2023 Oct 25; 20(3):14791641231172139. PubMed ID: 37208852
    [Abstract] [Full Text] [Related]

  • 9. Glycogen synthase kinase‑3β is required for epithelial‑mesenchymal transition and barrier dysfunction in mouse podocytes under high glucose conditions.
    Guo J, Yang L, Qiao Y, Liu Z.
    Mol Med Rep; 2016 Nov 25; 14(5):4091-4098. PubMed ID: 27748847
    [Abstract] [Full Text] [Related]

  • 10. HGF protected against diabetic nephropathy via autophagy-lysosome pathway in podocyte by modulating PI3K/Akt-GSK3β-TFEB axis.
    Hou B, Li Y, Li X, Zhang C, Zhao Z, Chen Q, Zhang N, Li H.
    Cell Signal; 2020 Nov 25; 75():109744. PubMed ID: 32827692
    [Abstract] [Full Text] [Related]

  • 11. Long noncoding RNA SNHG5 promotes podocyte injury via the microRNA-26a-5p/TRPC6 pathway in diabetic nephropathy.
    Zhou Y, Li ZL, Ding L, Zhang XJ, Liu NC, Liu SS, Wang YF, Ma RX.
    J Biol Chem; 2022 Dec 25; 298(12):102605. PubMed ID: 36257404
    [Abstract] [Full Text] [Related]

  • 12. Circ-0000953 deficiency exacerbates podocyte injury and autophagy disorder by targeting Mir665-3p-Atg4b in diabetic nephropathy.
    Liu X, Jiang L, Zeng H, Gao L, Guo S, Chen C, Liu X, Zhang M, Ma L, Li Y, Qi X, Wu Y.
    Autophagy; 2024 May 25; 20(5):1072-1097. PubMed ID: 38050963
    [Abstract] [Full Text] [Related]

  • 13. HGF alleviates high glucose-induced injury in podocytes by GSK3β inhibition and autophagy restoration.
    Zhang C, Hou B, Yu S, Chen Q, Zhang N, Li H.
    Biochim Biophys Acta; 2016 Nov 25; 1863(11):2690-2699. PubMed ID: 27526674
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Placenta-derived mesenchymal stem cells protect against diabetic kidney disease by upregulating autophagy-mediated SIRT1/FOXO1 pathway.
    Liu H, Wang J, Yue G, Xu J.
    Ren Fail; 2024 Dec 25; 46(1):2303396. PubMed ID: 38234193
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. GPR43 deficiency protects against podocyte insulin resistance in diabetic nephropathy through the restoration of AMPKα activity.
    Lu J, Chen PP, Zhang JX, Li XQ, Wang GH, Yuan BY, Huang SJ, Liu XQ, Jiang TT, Wang MY, Liu WT, Ruan XZ, Liu BC, Ma KL.
    Theranostics; 2021 Dec 25; 11(10):4728-4742. PubMed ID: 33754024
    [Abstract] [Full Text] [Related]

  • 19. Integrated Network Pharmacology and Cellular Assay to Explore the Mechanisms of Selenized Tripterine Phytosomes (Se@Tri-PTs) Alleviating Podocyte Injury in Diabetic Nephropathy.
    Zhu S, Liu Q, Chang Y, Luo C, Zhang X, Sun S.
    Curr Pharm Des; 2023 Dec 25; 29(38):3073-3086. PubMed ID: 37961864
    [Abstract] [Full Text] [Related]

  • 20. MiR-138 plays an important role in diabetic nephropathy through SIRT1-p38-TTP regulatory axis.
    Liu F, Guo J, Qiao Y, Pan S, Duan J, Liu D, Liu Z.
    J Cell Physiol; 2021 Sep 25; 236(9):6607-6618. PubMed ID: 33843045
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.